Skip to main content

Advertisement

Log in

Intravenous immunoglobulin in the treatment of resistant subacute cutaneous lupus erythematosus: a possible alternative

  • Case Report
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Subacute cutaneous lupus erythematosus (SCLE) is a common manifestation of systemic lupus erythematosus. In many cases it appears to be resistant to various systemic or topical treatments. Three cases of resistant SCLE with good response to intravenous immunoglobulin (IVIG) are described here suggesting that IVIG could be an alternative treatment in these patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Sontheimer RD (2005) Subacute cutaneous lupus erythematosus: 25-year evolution of a prototypic subset (subphenotype) of lupus erythematosus defined by characteristic cutaneous, pathological, immunological and genetic findings. Autoimmun Rev 4:253–263

    Article  PubMed  CAS  Google Scholar 

  2. Parodi A, Caproni M, Cardinali C, Bernacchi E, Fuligni A, De Panfilis G et al (2000) Clinical, histological and immunopathological features of 58 patients with subacute cutaneous lupus erythematosus. A review by the Italian group of immunodermatology. Dermatology 200:6–10

    Article  PubMed  CAS  Google Scholar 

  3. Dalakas MC (1998) Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases. Neurology 51:S2–S8

    PubMed  CAS  Google Scholar 

  4. Toubi E, Kessel A, Shoenfeld Y (2005) High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus. Hum Immunol 66:395–402

    Article  PubMed  CAS  Google Scholar 

  5. Stangel M, Gold R (2005) Intravenous immunoglobulins in MS. Int MS J 12:5–10

    PubMed  CAS  Google Scholar 

  6. Danieli MG, Cappelli M, Malcangi G, Logullo F, Salvi A, Danieli G (2004) Long term effectiveness of intravenous immunoglobulin in Churg–Strauss syndrome. Ann Rheum Dis 63:1649–1654

    Article  PubMed  CAS  Google Scholar 

  7. D’ Cruz DP, Hughes GR (2005) The treatment of lupus nephritis. BMJ 330:377–378

    Article  PubMed  Google Scholar 

  8. Dalakas MC (2004) Intravenous immunoglobulin in autoimmune neuromuscular diseases. JAMA 291:2367–2377

    Article  PubMed  CAS  Google Scholar 

  9. Shoenfeld Y, Katz U (2005) IVIg therapy in autoimmunity and related disorders: our experience with a large cohort of patients. Autoimmunity 38:123–137

    Article  PubMed  CAS  Google Scholar 

  10. Whitington PF, Hibbard JU (2004) High-dose immunoglobulin during pregnancy for recurrent neonatal haemochromatosis. Lancet 364:1690–1698

    Article  PubMed  CAS  Google Scholar 

  11. Mosca M, Strigini F, Carmignani A, D’ Ascanio A, Genazzani AR, Bombardieri S (2005) Pregnant patient with dermatomyositis successfully treated with intravenous immunoglobulin therapy. Arthritis Rheum 53:119–121

    Article  PubMed  CAS  Google Scholar 

  12. Ruetter A, Luger TA (2004) Efficacy and safety of intravenous immunoglobulin for immune-mediated skin disease: current view. Am J Clin Dermatol 5:153–160

    Article  PubMed  Google Scholar 

  13. Goodfield M, Davison K, Bowden K (2004) Intravenous immunoglobulin (IVIg) for therapy-resistant cutaneous lupus erythematosus (LE). J Dermatolog Treat 15:46–50

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to David P. D’ Cruz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lampropoulos, C.E., Hughes, G.R.V. & Cruz, D.P.D. Intravenous immunoglobulin in the treatment of resistant subacute cutaneous lupus erythematosus: a possible alternative. Clin Rheumatol 26, 981–983 (2007). https://doi.org/10.1007/s10067-006-0222-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-006-0222-5

Keywords

Navigation